Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Sarcoma 2Neoplasms 2Neuroblastoma 1Neoplastic Syndromes, Hereditary 1Neoplasm Metastasis 1Hereditary Breast and Ovarian Cancer Syndrome 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 32Cisplatin 31durvalumab 15pembrolizumab 14Fluorouracil 13Oxaliplatin 12Leucovorin 12Capecitabine 10Bevacizumab 8lenvatinib 7Nivolumab 7zanidatamab 4Trastuzumab 4S 1 (combination) 4Paclitaxel 4Liquid Biopsy 4Irinotecan 4Carboplatin 4Albumin-Bound Paclitaxel 4tremelimumab 3tislelizumab 3irinotecan sucrosofate 3Injections 3Folfox protocol 3130-nm albumin-bound paclitaxel 3toripalimab 2pertuzumab 2niraparib 2ivosidenib 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × High-Throughput Nucleotide Sequencing × 1 year × Clear all
NCT05036486 2026-01-20

The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer

National Health Research Institutes, Taiwan

Active not recruiting
480 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡